Financing ·
Ascendis Pharma A/S closed a warrant exercise window on June 29, 2026, resulting in the issuance of 177,267 ordinary…
ASNDAscendis Pharma A/S
Ascendis Pharma A/S closed a warrant exercise window on June 29, 2026, resulting in the issuance of 177,267 ordinary shares. This increased the company's nominal share capital to DKK 66,189,926. The exercises were executed at an average cash consideration of approximately USD $121.57 per share. The company subsequently amended its articles of association to reflect the capital increase. Ascendis Pharma A/S is a biotechnology company focused on developing proprietary drug delivery technologies.